Sjogrens

RheumNow Podcast square

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD?  Ro52 makes a big entrance with all our ILD coverage this month.

Read Article
Sjogren's Disease Interstitial Lung Disease Dr. Nancy Carteron, a rheumatologist in northern California, discusses interstitial lung disease in Sjogren's disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/lA1vrBiar4
Dr. John Cush @RheumNow( View Tweet )
guidelines.recommendations.jpg

ERS/EULAR guidelines for CTD-related interstitial lung disease

Jack Cush, MD

The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in

Read Article
EULAR & European Respiratory Society have published clinical practice guidelines for ILD assoc w/ connective tissue diseases (SSc, RA, SjD, IIM, SLE, MCTD). 2 publications included Dz specific ILD management algorithms; use of Hi Res CT over Lung Bx; ILD risk factors

Dr. John Cush @RheumNow( View Tweet )

RheumNow Podcast square

September to Remember (9.5.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.

Read Article
Telitacicept, a BLyS (BAFF)/APRIL dual-target fusion drug, announced it has met the primary endpoint in its Phase III clinical trial in treating primary Sjögren's syndrome (pSS) in China. Primary endpoint was the change in ESSDAI score at Week 24. https://t.co/afOgpGLdV1 https://t.co/9EKbbrCgTL

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Sjögren's Graduates (8.22.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.

Read Article
Sjogren.eye.mouth

It's now called Sjögren Disease!

Jack Cush, MD

Sjögren syndrome is now Sjögren disease, according to recommendations stemming from the 2023 International Rome consensus for the nomenclature of Sjögren disease.

Read Article
Teaching You How to Think… (8.15.2025) Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogren's trial, to PT or not to PT, and aphorisms to live by. https://t.co/2MhzjNCUEW https://t.co/Mt9iEAYKsK

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Teaching You How to Think… (8.15.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogren's trial, to PT or not to PT, and  aphorisms to live by.

Read Article
Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. https://t.co/cIBhF3YJh3 https://t.co/YRTq6LEFhm

Links:

Dr. John Cush @RheumNow( View Tweet )
labs.tubes_.jpg

Inefficiencies of ANA Testing

Jack Cush, MD

The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs).

Read Article
SSB, > SSA, Abs are signif associated w/ abnormal DLCO (AUC 0.791) in Sjogrens syndrome, esp in assoc. w/ LIP- lymphocytic interstitial pneumonitis. These findings more likely in quadruple positive Sjogrens w/ RF/ANA/SSA/SSB positivity. https://t.co/s6IyRzfXiN https://t.co/rKDBovTOpl

Links:

Dr. John Cush @RheumNow( View Tweet )
SSB, > SSA, Abs are signif associated w/ abnormal DLCO (AUC 0.791) in Sjogrens syndrome, esp in assoc. w/ LIP- lymphocytic interstitial pneumonitis. These findings more likely in quadruple positive Sjogrens w/ RF/ANA/SSA/SSB positivity. https://t.co/s6IyRzfXiN https://t.co/J3bMowsrUQ

Links:

Dr. John Cush @RheumNow( View Tweet )
Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases During the Late-Breaking Abstract session at EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). https://t.co/5bjyaqTqSN https://t.co/i4mGMYfyNK

Links:

Dr. John Cush @RheumNow( View Tweet )
light bulb idea

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases

Md Yuzaiful Md Yusof, MRCP(UK), PhD

During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR

Read Article
#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens. ⭐️🌱STAR/CRESS response rates also favoured active treatment. Safe, accessible, affordable option for active disease. @RheumNow #EULAR2025 #LB0005

Mrinalini Dey @DrMiniDey( View Tweet )

#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for #Sjogren-Neuropathy. No superiority but clinical response was more complete & longer retention numerically favouring RTX. Support trial of BCDT in SjD @RheumNow https://t.co/87e6yFMRkk

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
🔺CTD-ILD radiological signs to look out for 👀 #CTD #ILD #UIP #NSIP #Fibrosis #scleroderma #systemicsclerosis #Sjogrens #Lupus By @IlliasulK https://t.co/hHupTz0bCy

Links:

Dr Gurdeep S Dulay @gurdeep_dulay( View Tweet )
Infusion/injxn-reactions (IRRs) w/ biologics studied in 1,832 RA pts - IRRs seen in 9.7% & were signif more common w/ being younger (OR1.79), secondary Sjögren's (OR 2.17), prior leflunomide (OR 1.5); but less common w/ Abatacept (OR 0.26) & tocilizumab (OR 0.42), golimumab (OR https://t.co/IaHajITWri
Dr. John Cush @RheumNow( View Tweet )
Pope

Lessons Learned from a Lupus Registry: Two sides of one coin?

Janet Pope, MD, MPH, FRCPC

I want to talk about a large Canadian registry that sometimes doesn't get as much airtime. Our group is called CaNIOS: Canadian Network for Improved Outcomes in SLE. We've enrolled more than a thousand patients, seen at least annually and some for many years. These patients are incident or

Read Article
Diabetes Prevention with Hydroxychloroquine in Sjogren’s A Taiwanese insurance claims analysis looked at HCQ use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset diabetes in pSS. Conversely, higher doses of https://t.co/GS07GVp5pC
Dr. John Cush @RheumNow( View Tweet )
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×